Overview

Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma

Status:
RECRUITING

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

This Phase II clinical study is a prospective, open-label, single-arm trial designed to evaluate the efficacy and safety of combining anti-PD-1 therapy (Serplulimab) with thymalfasin and the SOX chemotherapy regimen as a neoadjuvant treatment for patients with clinical stage III gastric or gastroesophageal junction(GEJ) adenocarcinoma.

Phase:

PHASE2

Details

Lead Sponsor:

Zekuan Xu

Treatments:

Oxaliplatin
Tegafur
Thymalfasin